Eighth Annual Anniversary Issue - 182 pages
Introduction - pgs. 1-8
Company Updates & Rankings - pgs. 9-176
Macro Market Commentary - pgs. 177-180
BSR Model Portfolio Update - pgs. 181-182

It's the big issue!

Welcome to our once-yearly effort to review all the companies in Biotech Stock Research's coverage universe. Our company turned ten this past May, but this is the eighth anniversary of the creation of the Biotech Stock Research Model Portfolio. Its creation was the dawn of our biotech-centric coverage, making this our Eighth Annual Anniversary Issue.

The companies appear in a specific order. Our research is predicated on the idea the only smart investment in development-stage biotechnology companies is a well-diversified one. The BSR Model Portfolio is the most visible manifestation of this important concept. Without limiting the importance of that point, we also realize most of our Subscribers will need to pick and choose among companies in order to begin the diversification process. We've organized the issue with the diversification process in mind. We've placed the companies in order beginning with those most deserving of being a member of a diversified portfolio.

Special Offer:
For a limited time only (until September 24, 2009), you can have the Anniversary Issue shipped to you or you can pick it up from your local FedEX Kinkos store. The cost for this service is $35 and it is available in the USA only. For more details, click here.

In this issue of Biotech Monthly, we update our coverage on (in alphabetical order):

Amicus Therapeutics (FOLD)
ARyX (ARYX)
BioMarin (BMRN)
Corcept Therapeutics (CORT)
Dendreon (DNDN)
Discovery Labs (DSCO)
Dynavax Technologies (DVAX)
Hana Biosciences (HNAB)
Inovio (INO)
Oncolytics Biotech (ONCY)
Osmetech (London:OMH)
OXiGENE (OXGN)
Raptor Pharmaceuticals (RPTP)
Repros Therapeutics (RPRX)
Resverlogix (Toronto:RVX)
SciClone (SCLN)
Seattle Genetics (SGEN)
YM Biosciences (YMI)
ZymoGenetics (ZGEN)